{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:44:40Z","timestamp":1790304280184,"version":"4.1.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,9]]},"DOI":"10.7759\/cureus.71131","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T08:09:55Z","timestamp":1728461395000},"source":"Crossref","is-referenced-by-count":9,"title":["Cobenfy (Xanomeline-Trospium Chloride): A New Frontier in Schizophrenia Management"],"prefix":"10.7759","author":[{"given":"Abdul Haseeb","family":"Hasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ali","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01730-X","article-title":"Schizophrenia","volume":"399","author":"Jauhar S","year":"2022","unstructured":"Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. The Lancet. 2022, 399:473-86. 10.1016\/S0140-6736(21)01730-X","journal-title":"The Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ph17050610","article-title":"The new horizon of antipsychotics beyond the classic dopaminergic hypothesis\u2014the case of the xanomeline-trospium combination: a systematic review","volume":"17","author":"Vasiliu O","year":"2024","unstructured":"Vasiliu O, Budeanu B, C\u0103t\u0103nescu M\u0218. The new horizon of antipsychotics beyond the classic dopaminergic hypothesis\u2014the case of the xanomeline-trospium combination: a systematic review. Pharmaceuticals (Basel). 2024, 17:610. 10.3390\/ph17050610","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref3","unstructured":"FDA OKs first-in-class antipsychotic for schizophrenia. (2024). Accessed. September 28, 2024: https:\/\/www.medscape.com\/viewarticle\/fda-oks-first-class-antipsychotic-schizophrenia-2024a1000hno."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul I","year":"2024","unstructured":"Kaul I, Sawchak S, Correll CU, et al.. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet Lond Engl. 2024, 403:160-70. 10.1016\/S0140-6736(23)02190-6","journal-title":"Lancet Lond Engl"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","volume":"81","author":"Kaul I","year":"2024","unstructured":"Kaul I, Sawchak S, Walling DP, et al.. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2024, 81:749-56. 10.1001\/jamapsychiatry.2024.0785","journal-title":"JAMA Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/306991-cobenfy-xanomeline-trospium-chloride-a-new-frontier-in-schizophrenia-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T08:09:59Z","timestamp":1728461399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/306991-cobenfy-xanomeline-trospium-chloride-a-new-frontier-in-schizophrenia-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":5,"URL":"https:\/\/doi.org\/10.7759\/cureus.71131","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,9]]}}}